Pulmonary Arterial Hypertension: The Diagnosis You Don't Want to Miss

AMA/ANCC/ACPE Activity - Lecture Library Slide Set
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.
PAH is characterized by increased pulmonary vascular resistance due to remodeling and occlusion of the pulmonary arterioles, resulting in right heart failure and death within 2-3 years of diagnosis if untreated. Despite advances in the diagnosis and treatment of PAH over the last two decades, the prognosis is still poor. Early recognition of disease, institution of effective PAH disease-specific therapy optimized for disease severity, and comprehensive care in specialized centers hold the promise of improving the outcome of patients. PAH is often misdiagnosed or unrecognized in clinical practice and delaying treatment options can worsen outcomes and survival. Diagnostic tests are needed to be done on anyone with unexplained dyspnea and suspected PAH. This on-demand presentation is designed using a case-based, interactive discussion on tools to improve the diagnosis of PAH and the importance of early referral.
FACULTY
Jean Elwing, MD
Professor of Medicine
Director, Pulmonary Hypertension Program
University of Cincinnati
Review the activity at bit.ly/3oNwWAM and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.
This activity is jointly provided by the University of Nebraska Medical Center, Duquesne University School of Pharmacy and Practice Point Communications
Supported by independent educational grants from United Therapeutics Corporation, Bayer U.S. and Actelion Pharmaceuticals U.S., Inc., A Janssen Pharmaceutical Company of Johnson & Johnson
#freecme #pah #pulmonaryhypertension #practicepointcme